{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T05:43:10Z","timestamp":1781588590174,"version":"3.54.5"},"reference-count":14,"publisher":"Georg Thieme Verlag KG","issue":"22","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Dtsch Med Wochenschr"],"published-print":{"date-parts":[[2025,11]]},"abstract":"<jats:title>Was ist neu?<\/jats:title>\n                  <jats:p>Die 2024 aktualisierten Leitlinien der europ\u00e4ischen Organisation f\u00fcr Morbus Crohn und Colitis ulcerosa (ECCO) ordnen die vielf\u00e4ltigen medikament\u00f6sen und chirurgischen Therapieans\u00e4tze kritisch ein. Im Hinblick auf Behandlungsstrukturen und Therapieziele empfehlen sie die Etablierung multidisziplin\u00e4rer Behandlungsteams f\u00fcr eine strukturierte und qualit\u00e4tsgesicherte Behandlung mit gemeinsamer Entscheidungsfindung mit den Betroffenen.<\/jats:p>\n                  <jats:p>Eine Therapie sollte nach dem \u201eTreat-to-Target\u201c-Prinzip \u00fcberwacht und angepasst werden. In den Empfehlungen tritt die konventionelle medikament\u00f6se Therapie zunehmend in den Hintergrund. 5-Aminosalizylate sollen bei Morbus Crohn nicht und Kortikosteroide allenfalls kurzfristig im Schub eingesetzt werden. Der Stellenwert von Thiopurinen wird aufgrund des Nebenwirkungspotenzials und der im Vergleich zu den Behandlungsalternativen unterlegenen Wirksamkeit zur\u00fcckhaltend gesehen.<\/jats:p>\n                  <jats:p>Die Auswahl von fortgeschrittenen Therapien erfolgt aufgrund patientenindividueller Faktoren. Hier kommen zun\u00e4chst meist TNF-Antik\u00f6rper zum Einsatz. Vergleichende Studien sind rar. In der Erstlinientherapie sind Adalimumab und Ustekinumab gleich gut wirksam, nach Versagen von TNF-Antik\u00f6rpern ist der IL-23-Antik\u00f6rper Risankizumab einer Behandlung mit Ustekinumab \u00fcberlegen.<\/jats:p>\n                  <jats:p>Eine Ern\u00e4hrungstherapie mit enteraler Formeldi\u00e4t kann bei Kindern oder Erwachsenen mit guter Compliance versucht werden. Andere Ern\u00e4hrungsformen wie die mediterrane Di\u00e4t sind eher zur Remissionserhaltung geeignet.<\/jats:p>\n                  <jats:p>Eine chirurgische Therapie des Morbus Crohn stellt zunehmend auch in fr\u00fchen Krankheitsstadien eine sinnvolle Therapiealternative dar, die langfristige Komplikationen und langj\u00e4hrige medikament\u00f6se Therapien zu vermeiden hilft. Operationen werden m\u00f6glichst minimalinvasiv durchgef\u00fchrt, wobei vor allem der pr\u00e4operativen Vorbereitung (Reduktion von Kortikosteroiden, Korrektur von Mangelern\u00e4hrung) eine wichtige Rolle zukommt.<\/jats:p>","DOI":"10.1055\/a-2465-2352","type":"journal-article","created":{"date-parts":[[2025,10,28]],"date-time":"2025-10-28T23:58:13Z","timestamp":1761695893000},"page":"1329-1334","source":"Crossref","is-referenced-by-count":1,"title":["Morbus Crohn \u2013 die neuen europ\u00e4ischen Therapieleitlinien"],"prefix":"10.1055","volume":"150","author":[{"given":"Teresa","family":"Hof","sequence":"additional","affiliation":[{"name":"Klinik f\u00fcr Innere Medizin II, Universit\u00e4tsklinikum Freiburg, Freiburg"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hannes","family":"Neeff","sequence":"additional","affiliation":[{"name":"Klinik f\u00fcr Allgemein- und Viszeralchirurgie, Universit\u00e4tklinikum Freiburg, Freiburg"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Hasselblatt","sequence":"additional","affiliation":[{"name":"Klinik f\u00fcr Innere Medizin II, Universit\u00e4tsklinikum Freiburg, Freiburg"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"194","published-online":{"date-parts":[[2025,10,28]]},"reference":[{"key":"ref1","doi-asserted-by":"publisher","first-page":"1531","DOI":"10.1093\/ecco-jcc\/jjae091","article-title":"ECCO Guidelines on Therapeutics in Crohn's Disease: Medical Treatment","volume":"18","author":"H Gordon","year":"2024","journal-title":"J Crohns Colitis"},{"key":"ref2","doi-asserted-by":"publisher","first-page":"1556","DOI":"10.1093\/ecco-jcc\/jjae089","article-title":"ECCO Guidelines on Therapeutics in Crohn's Disease: Surgical Treatment","volume":"18","author":"M Adamina","year":"2024","journal-title":"J Crohns Colitis"},{"key":"ref3","doi-asserted-by":"publisher","first-page":"1082","DOI":"10.1111\/apt.17926","article-title":"Inflammatory bowel disease (IBD) patients with impaired quality of life on biologic therapy benefit from the support of an IBD nurse specialist: Results of a randomised controlled trial in Germany (IBD(BIO-ASSIST) study)","volume":"59","author":"B Bokemeyer","year":"2024","journal-title":"Aliment Pharmacol Ther"},{"key":"ref4","doi-asserted-by":"publisher","first-page":"1570","DOI":"10.1053\/j.gastro.2020.12.031","article-title":"STRIDE-II: An Update on the Selecting Therapeutic Targets in Inflammatory Bowel Disease (STRIDE) Initiative of the International Organization for the Study of IBD (IOIBD): Determining Therapeutic Goals for Treat-to-Target strategies in IBD","volume":"160","author":"D Turner","year":"2021","journal-title":"Gastroenterology"},{"key":"ref5","doi-asserted-by":"publisher","first-page":"2779","DOI":"10.1016\/S0140-6736(17)32641-7","article-title":"Effect of tight control management on Crohn's disease (CALM): a multicentre, randomised, controlled phase 3 trial","volume":"390","author":"JF Colombel","year":"2017","journal-title":"Lancet"},{"key":"ref6","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1053\/j.gastro.2020.03.039","article-title":"Deep Remission at 1 Year Prevents Progression of Early Crohn's Disease","volume":"159","author":"RC Ungaro","year":"2020","journal-title":"Gastroenterology"},{"key":"ref7","doi-asserted-by":"publisher","first-page":"415","DOI":"10.1016\/S2468-1253(24)00034-7","article-title":"A biomarker-stratified comparison of top-down versus accelerated step-up treatment strategies for patients with newly diagnosed Crohn's disease (PROFILE): a multicentre, open-label randomised controlled trial","volume":"9","author":"NM Noor","year":"2024","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"ref8","doi-asserted-by":"publisher","first-page":"2200","DOI":"10.1016\/S0140-6736(22)00688-2","article-title":"Ustekinumab versus adalimumab for induction and maintenance therapy in biologic-naive patients with moderately to severely active Crohn's disease: a multicentre, randomised, double-blind, parallel-group, phase 3b trial","volume":"399","author":"BE Sands","year":"2022","journal-title":"Lancet"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1093\/ecco-jcc\/jjaf051","article-title":"Comparative real-world effectiveness of ustekinumab versus anti-TNF in Crohn's disease: 12-month maintenance phase results from the prospective, observational RUN-CD study using propensity score adjustment","volume":"19","author":"B Bokemeyer","year":"2025","journal-title":"J Crohns Colitis"},{"key":"ref10","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1056\/NEJMoa2314585","article-title":"Risankizumab versus Ustekinumab for Moderate-to-Severe Crohn's Disease","volume":"391","author":"L Peyrin-Biroulet","year":"2024","journal-title":"N Engl J Med"},{"key":"ref11","doi-asserted-by":"publisher","first-page":"2289","DOI":"10.1093\/ibd\/izad315","article-title":"Real-world Effectiveness and Safety of Risankizumab in Patients with Moderate to Severe Multirefractory Crohn's Disease: A Belgian Multicentric Cohort Study","volume":"30","author":"D Alsoud","year":"2024","journal-title":"Inflamm Bowel Dis"},{"key":"ref12","doi-asserted-by":"publisher","first-page":"952","DOI":"10.1053\/j.gastro.2024.12.031","article-title":"Mechanistic Implications of the Mediterranean Diet in Patients With Newly Diagnosed Crohn's Disease: Multiomic Results From a Prospective Cohort","volume":"168","author":"L Godny","year":"2025","journal-title":"Gastroenterology"},{"key":"ref13","doi-asserted-by":"publisher","first-page":"900","DOI":"10.1016\/S2468-1253(20)30117-5","article-title":"Laparoscopic ileocaecal resection versus infliximab for terminal ileitis in Crohn's disease: retrospective long-term follow-up of the LIR!C trial","volume":"5","author":"TW Stevens","year":"2020","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"ref14","doi-asserted-by":"publisher","first-page":"976","DOI":"10.1053\/j.gastro.2023.05.051","article-title":"Early Ileocecal Resection for Crohn's Disease Is Associated With Improved Long-term Outcomes Compared With Anti-Tumor Necrosis Factor Therapy: A Population-Based Cohort Study","volume":"165","author":"M Agrawal","year":"2023","journal-title":"Gastroenterology"}],"container-title":["DMW - Deutsche Medizinische Wochenschrift"],"original-title":[],"language":"de","link":[{"URL":"http:\/\/www.thieme-connect.de\/products\/ejournals\/pdf\/10.1055\/a-2465-2352.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,28]],"date-time":"2025-10-28T23:58:14Z","timestamp":1761695894000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.thieme-connect.de\/DOI\/DOI?10.1055\/a-2465-2352"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,28]]},"references-count":14,"journal-issue":{"issue":"22","published-online":{"date-parts":[[2025,10,28]]},"published-print":{"date-parts":[[2025,11]]}},"URL":"https:\/\/doi.org\/10.1055\/a-2465-2352","archive":["Portico","CLOCKSS"],"relation":{},"ISSN":["0012-0472","1439-4413"],"issn-type":[{"value":"0012-0472","type":"print"},{"value":"1439-4413","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,10,28]]}}}